Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Sells 5,000 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Michael Raab sold 5,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $11.16, for a total transaction of $55,800.00. Following the sale, the director now owns 13,895 shares in the company, valued at $155,068.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of NASDAQ:FOLD traded up $0.48 during mid-day trading on Friday, hitting $12.48. The company had a trading volume of 9,669,534 shares, compared to its average volume of 2,870,645. The firm has a market capitalization of $2.77 billion, a P/E ratio of -9.38 and a beta of 1.87. The company has a fifty day moving average of $12.00. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.33 and a quick ratio of 7.21. Amicus Therapeutics, Inc. has a one year low of $8.27 and a one year high of $16.82.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.09). The business had revenue of $34.00 million for the quarter, compared to the consensus estimate of $37.82 million. Amicus Therapeutics had a negative net margin of 386.18% and a negative return on equity of 64.11%. The business’s revenue was up 103.6% on a year-over-year basis. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Several research firms have issued reports on FOLD. Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a report on Monday, April 22nd. Janney Montgomery Scott began coverage on shares of Amicus Therapeutics in a report on Friday, April 5th. They set a “buy” rating and a $13.91 price target for the company. ValuEngine upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. HC Wainwright began coverage on shares of Amicus Therapeutics in a report on Monday, June 17th. They set a “buy” rating and a $18.00 price target for the company. Finally, Cantor Fitzgerald set a $20.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $18.06.

A number of hedge funds have recently made changes to their positions in FOLD. Redmile Group LLC boosted its holdings in shares of Amicus Therapeutics by 135.7% in the 1st quarter. Redmile Group LLC now owns 19,616,062 shares of the biopharmaceutical company’s stock worth $266,778,000 after buying an additional 11,292,845 shares during the last quarter. FMR LLC boosted its holdings in shares of Amicus Therapeutics by 33.3% in the 4th quarter. FMR LLC now owns 17,943,523 shares of the biopharmaceutical company’s stock worth $171,900,000 after buying an additional 4,479,743 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Amicus Therapeutics by 0.9% in the 4th quarter. BlackRock Inc. now owns 16,521,820 shares of the biopharmaceutical company’s stock worth $158,279,000 after buying an additional 147,484 shares during the last quarter. venBio Select Advisor LLC boosted its holdings in shares of Amicus Therapeutics by 8.5% in the 4th quarter. venBio Select Advisor LLC now owns 10,125,000 shares of the biopharmaceutical company’s stock worth $96,998,000 after buying an additional 791,868 shares during the last quarter. Finally, Marshall Wace North America L.P. boosted its holdings in shares of Amicus Therapeutics by 20.9% in the 1st quarter. Marshall Wace North America L.P. now owns 6,430,019 shares of the biopharmaceutical company’s stock worth $87,448,000 after buying an additional 1,113,735 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Story: What is a good rate of return for a mutual fund?

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.